S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12

Omega Therapeutics Stock Forecast, Price & News

-1.10 (-6.08%)
(As of 12/1/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
61,913 shs
Average Volume
100,101 shs
Market Capitalization
$811.70 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive OMGA News and Ratings via Email

Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Omega Therapeutics logo

About Omega Therapeutics

Omega Therapeutics Inc. is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines. Omega Therapeutics Inc. is based in CAMBRIDGE, Mass.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$4.61 per share


Pretax Margin




Free Float
Market Cap
$811.70 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.67 out of 5 stars

Medical Sector

966th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

148th out of 202 stocks

Analyst Opinion: 3.4Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Omega Therapeutics (NASDAQ:OMGA) Frequently Asked Questions

Is Omega Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Omega Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Omega Therapeutics stock.
View analyst ratings for Omega Therapeutics
or view top-rated stocks.

When is Omega Therapeutics' next earnings date?

Omega Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Omega Therapeutics

How were Omega Therapeutics' earnings last quarter?

Omega Therapeutics Inc (NASDAQ:OMGA) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.57) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.09.
View Omega Therapeutics' earnings history

What price target have analysts set for OMGA?

4 Wall Street analysts have issued twelve-month price targets for Omega Therapeutics' stock. Their forecasts range from $22.00 to $36.00. On average, they anticipate Omega Therapeutics' stock price to reach $29.50 in the next year. This suggests a possible upside of 73.6% from the stock's current price.
View analysts' price targets for Omega Therapeutics
or view top-rated stocks among Wall Street analysts.

When did Omega Therapeutics IPO?

(OMGA) raised $126 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share.

What is Omega Therapeutics' stock symbol?

Omega Therapeutics trades on the NASDAQ under the ticker symbol "OMGA."

When does Omega Therapeutics' lock-up period expire?

Omega Therapeutics' lock-up period expires on Wednesday, January 26th. Omega Therapeutics had issued 7,400,000 shares in its public offering on July 30th. The total size of the offering was $125,800,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Who are Omega Therapeutics' major shareholders?

Omega Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include HarbourVest Partners LLC (5.54%), Artal Group S.A. (4.76%), CHI Advisors LLC (2.21%), BlackRock Inc. (2.01%), Sphera Funds Management LTD. (1.11%) and Platinum Investment Management Ltd. (1.05%).

Which major investors are buying Omega Therapeutics stock?

OMGA stock was acquired by a variety of institutional investors in the last quarter, including HarbourVest Partners LLC, Artal Group S.A., CHI Advisors LLC, BlackRock Inc., Sphera Funds Management LTD., Platinum Investment Management Ltd., Monashee Investment Management LLC, and 72 Investment Holdings LLC.

How do I buy shares of Omega Therapeutics?

Shares of OMGA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omega Therapeutics' stock price today?

One share of OMGA stock can currently be purchased for approximately $16.99.

How much money does Omega Therapeutics make?

Omega Therapeutics has a market capitalization of $811.70 million.

How many employees does Omega Therapeutics have?

Omega Therapeutics employs 2,021 workers across the globe.

What is Omega Therapeutics' official website?

The official website for Omega Therapeutics is www.omegatherapeutics.com.

Where are Omega Therapeutics' headquarters?

Omega Therapeutics is headquartered at 20 ACORN PARK DRIVE, CAMBRIDGE MA, 02140.

How can I contact Omega Therapeutics?

Omega Therapeutics' mailing address is 20 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-949-4360 or via email at [email protected].

This page was last updated on 12/2/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.